Lenalidomida Olainfarm (Lenalidomide)

Lenalidomide binds to the cereblon component of an E3 ubiquitin ligase complex, changing the complex’s target proteins. This leads to the degradation of transcription factors Ikaros and Aiolos, which are important for the survival of malignant cells. The result is reduced tumor growth, altered cytokine production, inhibition of new blood‑vessel formation, and enhanced immune‑mediated killing of cancer cells.

The specific dose of Lenalidomida Olainfarm is set by the prescribing clinician based on the approved indication, the patient’s overall health, renal and hepatic function, and any concomitant medications. Because dosing can vary widely, patients should follow the exact regimen written on their prescription and not adjust the amount on their own.

Lenalidomida Olainfarm is classified as Pregnancy Category X, meaning it is known to cause fetal harm and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception before, during, and after treatment. The drug is also not recommended while breastfeeding because it may pass into breast milk and affect the infant.

To request Lenalidomida Olainfarm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled logistics), and the necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy. Lenalidomide also has stronger anti‑angiogenic and anti‑proliferative effects, making it the preferred option for many patients with multiple myeloma or 5q‑deleted myelodysplastic syndromes, while thalidomide may still be used in specific circumstances.

Lenalidomida Olainfarm should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in areas where temperature may exceed the recommended range, and keep it out of reach of children.

Lenalidomida Olainfarm is taken orally, usually as a whole tablet swallowed with water. It may be taken with or without food, depending on the prescriber’s instructions. Patients should not crush, split, or chew the tablet unless specifically advised, and they should follow the dosing schedule provided by their healthcare professional.

The most serious risks include the potential for venous thromboembolism (blood clots), severe neutropenia that can lead to life‑threatening infections, secondary primary malignancies, and significant liver toxicity. Patients should be monitored closely for signs of these events, and any concerning symptoms should be reported to a healthcare provider immediately.

Lenalidomida Olainfarm should not be used by pregnant women, individuals with uncontrolled infections, or patients with severe renal or hepatic impairment without dose adjustment. It is also contraindicated in patients who cannot adhere to strict contraception requirements or who have a known hypersensitivity to lenalidomide or any of its excipients.